Selecting the Treatment Eye and Overcoming Implementation Barriers in MacTel Type 2 Management

A panelist discusses how clinical strategy and logistical coordination are key to implementing NT-501 successfully in macular telangiectasia (MacTel) management. Using a patient case, they examined prioritizing treatment for the better-seeing eye to sustain visual function, acknowledging that eyes with severe damage may offer limited gains. The group then explored real-world barriers to broader therapy adoption, including device cost, reimbursement issues, and institutional hesitancy to invest in stock. Proposed solutions included partnering with specialty pharmacies, leveraging manufacturer support, and building payer awareness. The surgical learning curve was described as manageable, emphasizing the importance of proper suturing technique and early referral for eligible patients. Overall, the segment underscored that the clinical value of NT-501 depends not only on selecting the right eye but also on overcoming systemic and administrative challenges to ensure access and continuity of care.